South Korea Medical Cannabis Program: Regulations, Access & Policy Updates

Executive Summary

South Korea operates one of Asia's most restrictive medical cannabis programs, permitting only imported pharmaceutical-grade products for a narrow list of severe conditions since March 2019. The program emerged from amendments to the Narcotics Control Act that created a tightly regulated exception to the country's decades-old prohibition framework. As of July 2026, fewer than 100 patients have accessed legal medical cannabis through the system, primarily epilepsy patients using Epidiolex and rare-disease sufferers prescribed Sativex. Recent legislative proposals seek to replace imported products with domestically cultivated alternatives, marking a potential shift in a program that has remained largely symbolic since its inception. South Korea's approach reflects broader East Asian conservatism toward cannabis policy while responding to international pharmaceutical developments and patient advocacy pressure. The program's evolution carries implications for regional policy diffusion, pharmaceutical market access in Asia, and the global medical cannabis supply chain.

Why This Matters

South Korea's medical cannabis framework represents the first legal cannabis access in a major East Asian economy, creating precedent for regional policy development. The country's 51 million residents live under some of the world's strictest drug laws, where cannabis possession carries mandatory prison sentences and social stigma remains severe. The 2019 legalization, though limited, marked a historic departure from absolute prohibition in a region where cannabis policy reform has lagged decades behind Western nations. For the pharmaceutical industry, South Korea represents a $25 billion healthcare market with high per-capita spending and sophisticated medical infrastructure. GW Pharmaceuticals (now Jazz Pharmaceuticals) and other international manufacturers view the country as a gateway to broader Asian market access. The current import-only model has generated approximately $2-3 million in annual medical cannabis sales since 2020, according to Korea Pharmaceutical Traders Association data. Patient advocacy groups estimate 50,000-100,000 South Koreans could benefit from medical cannabis access for conditions including epilepsy, multiple sclerosis, chemotherapy side effects, and chronic pain. The restrictive qualifying conditions and complex approval process have created a gap between legal framework and practical access. Families of pediatric epilepsy patients drove initial reform efforts after high-profile cases of parents facing prosecution for importing CBD oil. The proposed shift to domestic cultivation carries economic implications beyond patient access. South Korean agricultural technology companies and pharmaceutical manufacturers see opportunities in controlled cultivation, extraction, and formulation. The Ministry of Food and Drug Safety estimates domestic production could reduce costs by 40-60% compared to imported products while creating 500-1,000 specialized jobs in cultivation and processing facilities.

Background and History

Prohibition Era: 1970s-2010s

South Korea criminalized cannabis in 1976 under the Narcotics Control Act, implementing penalties among the harshest in developed nations. The law classified cannabis alongside heroin and methamphetamine as a Schedule I narcotic, carrying sentences of up to five years imprisonment for simple possession and life imprisonment for trafficking. The framework emerged during Park Chung-hee's authoritarian government as part of broader social control measures. Throughout the 1980s and 1990s, cannabis remained virtually absent from public discourse. Detection rates stayed below 1,000 cases annually, with most involving foreign nationals or Korean citizens arrested abroad. The Korea Food and Drug Administration (predecessor to current regulatory bodies) maintained absolute prohibition without medical exceptions. Hemp cultivation, historically significant in Korean agriculture, remained legal only for industrial fiber production under strict licensing requiring THC content below 0.3%.

Early Reform Pressure: 2010-2017

International pharmaceutical developments began shifting the landscape in the 2010s. The 2013 approval of Sativex in multiple European countries and the 2015 U.S. FDA designation of Epidiolex as an orphan drug for pediatric epilepsy created pressure on Korean regulators to address medical access questions. In 2015, the family of a child with Lennox-Gastaut syndrome faced prosecution after importing CBD oil from the United States. The case, widely covered in Korean media, sparked the first significant public debate about medical cannabis. Parent advocacy groups formed, including the Korean Epilepsy Association's medical cannabis working group, which documented 200+ families seeking access to cannabinoid therapies. The Ministry of Health and Welfare commissioned a study in 2016 examining international medical cannabis frameworks. The report, delivered to the National Assembly in March 2017, recommended limited legalization for pharmaceutical-grade products in rare diseases. Conservative opposition remained strong, with the Korean Association Against Drug Abuse and the Korean Pharmaceutical Association both opposing any liberalization.

Legislative Breakthrough: 2018

On November 23, 2018, the National Assembly passed amendments to the Narcotics Control Act creating South Korea's first medical cannabis exception. The vote passed 198-0 with 6 abstentions, reflecting carefully negotiated compromise language that satisfied conservative concerns while creating legal access pathways. Representative Shin Chang-hyun of the Bareun Mirae Party sponsored the amendments, emphasizing the narrow scope and pharmaceutical focus. The legislative language specified that only products approved by the Ministry of Food and Drug Safety through standard drug approval processes would qualify, effectively limiting access to internationally approved medications like Epidiolex and Sativex. The amendments explicitly prohibited domestic cultivation, requiring all medical cannabis products to be imported through licensed pharmaceutical distributors. The Ministry of Food and Drug Safety published implementing regulations on February 12, 2019, establishing the approval process for physicians, pharmacies, and patients. The regulations created a three-tier authorization system requiring specialist physician recommendation, Ministry approval, and designated pharmacy dispensing.

Program Launch: March 2019

South Korea's medical cannabis program officially began on March 12, 2019, when the regulatory framework took effect. The Ministry of Food and Drug Safety designated 12 hospitals nationwide as authorized prescribing centers, all major academic medical centers with neurology or oncology specialties. Thirty pharmacies received initial dispensing licenses, concentrated in Seoul and major metropolitan areas. The qualifying conditions list included rare epilepsy syndromes (Dravet syndrome, Lennox-Gastaut syndrome), HIV/AIDS wasting syndrome, chemotherapy-induced nausea and vomiting, and multiple sclerosis spasticity. The Ministry explicitly excluded chronic pain, anxiety disorders, and other conditions covered in Western medical cannabis programs.

Early Implementation: 2019-2021

The first legal medical cannabis prescription in South Korea was filled on March 28, 2019, for a 9-year-old Dravet syndrome patient at Seoul National University Hospital. The prescription was for Epidiolex (cannabidiol oral solution), imported through a special Ministry authorization before formal product approval. Media coverage was extensive but carefully framed around the pharmaceutical nature of the treatment. By December 2019, only 37 patients had received medical cannabis prescriptions, according to Ministry of Food and Drug Safety data. Epidiolex accounted for 31 prescriptions, with Sativex (nabiximols) accounting for the remainder. The low uptake reflected multiple barriers: physician reluctance to prescribe due to regulatory complexity, high costs (₩500,000-1,200,000 monthly, or $420-1,000), lack of insurance coverage, and persistent social stigma. The Ministry approved Epidiolex through the standard New Drug Application process in June 2020, making it the first cannabis-derived medication with full Korean regulatory approval. The approval covered treatment of seizures associated with Lennox-Gastaut syndrome and Dravet syndrome in patients two years and older. Sativex received conditional approval in October 2020 for multiple sclerosis spasticity.

Expansion Discussions: 2022-2024

Patient advocacy groups petitioned for expanded access in 2022, submitting a proposal to the Ministry of Health and Welfare requesting addition of chronic pain, PTSD, and Parkinson's disease to qualifying conditions. The Ministry formed an expert advisory committee that delivered recommendations in August 2023 opposing expansion, citing insufficient clinical evidence and concerns about recreational use normalization. The Korean Medical Association surveyed members in 2023, finding that 68% of physicians opposed expanding medical cannabis access beyond current rare diseases. The survey highlighted concerns about prescribing liability, lack of clinical training, and social acceptability. Only 4% of respondents reported familiarity with cannabinoid pharmacology. International pharmaceutical companies lobbied for streamlined import processes and expanded indications. Jazz Pharmaceuticals, which acquired GW Pharmaceuticals in 2021, met with Ministry officials in 2024 to discuss broader Epidiolex access and potential clinical trials in Korean populations.

Domestic Production Proposal: 2025-2026

In January 2025, Representative Kim Min-seok introduced legislation to permit domestic cultivation of medical cannabis under government oversight. The proposal emerged from economic development concerns rather than patient access advocacy, emphasizing import substitution and agricultural technology opportunities. The bill proposed creating a state-controlled cultivation system similar to South Korea's opium poppy program for pharmaceutical morphine production. The Ministry of Agriculture, Food and Rural Affairs commissioned a feasibility study in mid-2025, examining controlled environment agriculture infrastructure and security requirements. The study, completed in March 2026, estimated startup costs of ₩15-20 billion ($12-16 million) for a 10,000-square-meter cultivation facility capable of producing 500 kg of dried cannabis annually. The July 2026 legislative proposal builds on this groundwork, seeking to amend the Narcotics Control Act to permit licensed domestic cultivation exclusively for pharmaceutical production. The bill maintains the import-only model for finished products while creating pathways for Korean pharmaceutical companies to develop domestically sourced formulations.

Key Players

Ministry of Food and Drug Safety

The Ministry of Food and Drug Safety (MFDS) serves as the primary regulatory authority for medical cannabis in South Korea. The agency oversees product approvals, physician authorizations, pharmacy licensing, and import controls. The MFDS Narcotics Policy Division, a 15-person unit within the Ministry, administers day-to-day program operations. Commissioner Oh Yu-kyoung, appointed in 2024, has emphasized pharmaceutical safety and evidence-based policy in public statements about medical cannabis regulation.

Ministry of Health and Welfare

The Ministry of Health and Welfare establishes qualifying conditions, oversees the National Health Insurance Service's coverage decisions, and coordinates with medical professional associations. The Ministry has maintained a conservative stance on program expansion, prioritizing rare diseases with strong clinical evidence. Minister Cho Kyu-hong has stated that broader access would require "overwhelming scientific consensus" and careful consideration of social impacts.

Jazz Pharmaceuticals

Jazz Pharmaceuticals, through its acquisition of GW Pharmaceuticals, holds the Korean marketing authorization for Epidiolex. The company supplies approximately 80% of medical cannabis products in the Korean market. Jazz has invested in Korean-language physician education programs and patient support services. The company employs a 12-person Korea team focused on rare epilepsy markets.

Almirall S.A.

Spanish pharmaceutical company Almirall holds Korean rights to Sativex through licensing agreements. The company has pursued multiple sclerosis specialist education and patient access programs. Sativex accounts for approximately 20% of Korean medical cannabis prescriptions, primarily through university hospital neurology departments.

Korean Epilepsy Association

The Korean Epilepsy Association, a patient advocacy organization founded in 1998, led initial reform efforts and continues to advocate for expanded access. The organization represents approximately 300,000 epilepsy patients in South Korea. Executive Director Lee Sang-do has testified before the National Assembly multiple times on medical cannabis access barriers.

Korean Medical Association

The Korean Medical Association (KMA), representing 130,000 physicians, has maintained cautious opposition to program expansion. The organization emphasizes physician liability concerns and the need for comprehensive clinical training before broader prescribing authority. The KMA's 2023 policy statement called for maintaining current restrictions while improving physician education on cannabinoid pharmacology.

Korean Pharmaceutical Association

The Korean Pharmaceutical Association, representing 70,000 pharmacists, has raised concerns about dispensing protocols, storage requirements, and liability frameworks. The organization has called for clearer regulatory guidance and enhanced pharmacist training. Approximately 50 pharmacies currently hold medical cannabis dispensing licenses, up from 30 at program launch.

Legal and Regulatory Framework

South Korea's medical cannabis program operates under amendments to the Narcotics Control Act (Act No. 15939) enacted November 23, 2018, and implemented March 12, 2019. The framework maintains cannabis classification as a Schedule I narcotic while creating narrow exceptions for approved pharmaceutical products. The Narcotics Control Act Article 4-2 establishes the medical cannabis exception, stating that "narcotics for medical purposes may be used within the scope prescribed by Presidential Decree." Presidential Decree No. 29542 specifies qualifying conditions, prescriber requirements, and import controls. The Ministry of Food and Drug Safety Regulation No. 2019-12 details application procedures, record-keeping requirements, and enforcement mechanisms. Qualifying conditions are defined by Ministry of Health and Welfare Notice No. 2019-47, currently limited to Dravet syndrome, Lennox-Gastaut syndrome, multiple sclerosis spasticity, HIV/AIDS wasting syndrome, and chemotherapy-induced nausea and vomiting refractory to standard treatments. The notice requires specialist physician diagnosis and documentation of treatment failure with at least two conventional therapies. Prescriber authorization requires specialist certification in neurology, oncology, or infectious disease, completion of a Ministry-approved training program (8 hours of instruction), and registration with the MFDS Narcotics Management System. As of June 2026, 247 physicians held active medical cannabis prescribing authority, according to Ministry data. Patient authorization follows a two-step process. First, an authorized physician submits an application to the MFDS including diagnosis documentation, treatment history, and justification for medical cannabis therapy. The Ministry reviews applications within 14 business days, with approval rates exceeding 90% for complete applications. Second, approved patients receive a medical cannabis identification card valid for six months, renewable upon physician re-certification. Pharmacy dispensing requires specialized licensing under Pharmaceutical Affairs Act Article 45-2. Licensed pharmacies must maintain separate locked storage for medical cannabis products, implement enhanced record-keeping systems, and report all dispensing to the MFDS within 24 hours. Pharmacists must complete a 4-hour training program on cannabinoid medications and dispensing protocols. Product approval follows standard pharmaceutical pathways under the Pharmaceutical Affairs Act. Manufacturers must submit New Drug Applications or Abbreviated New Drug Applications demonstrating safety and efficacy through clinical trials. The MFDS applies the same evidentiary standards to cannabis-derived medications as conventional pharmaceuticals. Approved products must meet Korean Pharmacopoeia standards for purity, potency, and consistency. Import controls require Ministry authorization for each shipment under Narcotics Control Act Article 7. Importers must be licensed pharmaceutical distributors with specialized narcotics handling permits. All imports enter through Incheon International Airport with customs inspection and MFDS verification. Import quantities are limited to three months of domestic demand based on prescription data. Penalties for violations remain severe. Unauthorized possession of medical cannabis products carries 1-5 years imprisonment under Narcotics Control Act Article 58. Physicians prescribing outside authorized conditions face license suspension and criminal prosecution. Diversion of medical cannabis products to non-patients constitutes trafficking under Article 59, carrying 5 years to life imprisonment. The proposed domestic cultivation framework would add new sections to the Narcotics Control Act establishing a licensing system for cultivation facilities. The July 2026 bill proposes limiting licenses to government research institutes and pharmaceutical companies with existing narcotics manufacturing permits. Cultivation would require Ministry of Agriculture approval in addition to MFDS authorization, with facilities subject to 24-hour video surveillance and quarterly inspections.

Market and Business Implications

South Korea's medical cannabis market generated approximately ₩3.2 billion ($2.7 million) in sales during 2025, representing 0.01% of the country's ₩30 trillion pharmaceutical market. The market remains dominated by imported products, with Jazz Pharmaceuticals' Epidiolex accounting for 78% of revenue and Almirall's Sativex comprising most of the remainder. Patient out-of-pocket costs range from ₩500,000 to ₩1,200,000 monthly ($420-1,000), as the National Health Insurance Service does not cover medical cannabis products. The high costs create significant access barriers, with patient advocacy groups estimating that 60-70% of approved patients discontinue treatment within six months due to financial constraints. Private insurance companies have uniformly excluded medical cannabis from coverage, citing the experimental nature of treatments and lack of long-term safety data. The proposed shift to domestic production could substantially alter market economics. The Ministry of Agriculture's 2026 feasibility study estimated that domestically cultivated cannabis could reduce raw material costs by 40-60% compared to imported products. Korean pharmaceutical companies have expressed interest in developing generic versions of Epidiolex and Sativex using domestic cultivation, potentially reducing patient costs to ₩300,000-700,000 monthly ($250-580). Three major Korean pharmaceutical companies—Hanmi Pharmaceutical, Celltrion, and Yuhan Corporation—have formed research consortia to explore medical cannabis product development. Hanmi announced in May 2026 that it had filed provisional patents for novel cannabinoid formulations and delivery systems. The company projects that domestic production authorization could create a ₩50-100 billion ($42-83 million) market opportunity by 2030 if qualifying conditions expand. Agricultural technology companies see opportunities in controlled environment cultivation. LG CNS, a subsidiary of LG Corporation, has developed smart greenhouse systems specifically designed for pharmaceutical cannabis cultivation, incorporating AI-driven climate control, automated nutrient delivery, and blockchain-based tracking. The company estimates the domestic cultivation infrastructure market at ₩20-30 billion ($17-25 million) in initial capital investment. The medical cannabis program has had minimal impact on South Korea's illicit cannabis market, which remains small compared to Western nations. The Supreme Prosecutors' Office reported 3,847 cannabis-related arrests in 2025, up 12% from 2024 but still representing less than 0.01% of the population. Most cases involve recreational use by young adults, with no evidence of diversion from the medical program. Street prices for illicit cannabis remain high at ₩30,000-50,000 per gram ($25-42), reflecting supply constraints and enforcement pressure. International pharmaceutical companies view South Korea as a potential model for other Asian markets. Japan, Taiwan, and Singapore have all studied the Korean framework as they consider medical cannabis policy. Jazz Pharmaceuticals has used Korean approval of Epidiolex in regulatory submissions to Japanese authorities. The company's Asia-Pacific strategy identifies South Korea, Japan, and Australia as priority markets for rare epilepsy treatments.

What Experts Say

Medical professionals remain divided on the appropriate scope of South Korea's medical cannabis program. Dr. Park Sung-pa, a pediatric neurologist at Seoul National University Hospital and one of the country's most active medical cannabis prescribers, has stated in published interviews that the current framework appropriately balances patient access with safety concerns for rare epilepsy cases. According to Dr. Park's 2025 presentation to the Korean Epilepsy Association, approximately 40% of his Dravet syndrome and Lennox-Gastaut syndrome patients who tried Epidiolex experienced clinically meaningful seizure reduction. Dr. Kim Hye-jin, a pain management specialist at Yonsei University Medical Center, has advocated for expanded access to include chronic pain conditions. In a 2024 editorial in the Korean Journal of Pain Medicine, Dr. Kim argued that excluding chronic pain patients from medical cannabis access lacks scientific justification given international evidence. She noted that South Korea's opioid prescribing rates remain among the lowest in developed nations, creating unmet needs for pain management alternatives. The Korean Medical Association's 2023 policy position, developed by a committee chaired by Dr. Lee Jae-ho, emphasized the need for caution in program expansion. According to the association's published statement, concerns include insufficient long-term safety data in Asian populations, potential for recreational use normalization, and lack of standardized clinical training for prescribers. The position called for maintaining current restrictions while investing in physician education and clinical research infrastructure. Pharmaceutical industry representatives have focused on regulatory efficiency and market access. In testimony to the National Assembly Health and Welfare Committee in March 2026, Jazz Pharmaceuticals Korea President Kim Sung-min stated that streamlined import processes and insurance coverage would significantly improve patient access without requiring domestic cultivation. The company's position emphasizes the complexity of pharmaceutical-grade cannabis production and the advantages of established international supply chains. Patient advocates have consistently pushed for broader access and reduced costs. Lee Sang-do, executive director of the Korean Epilepsy Association, stated in a June 2026 press conference that the current program serves fewer than 1% of patients who could potentially benefit from medical cannabis therapies. According to Lee, the primary barriers are cost, physician reluctance to prescribe, and overly restrictive qualifying conditions rather than product availability. Agricultural economists see domestic cultivation as an economic development opportunity. Dr. Choi Min-ho, a professor of agricultural economics at Seoul National University, published research in 2025 estimating that domestic medical cannabis cultivation could generate ₩100-150 billion ($83-125 million) in annual economic activity by 2030 under expanded access scenarios. The analysis projected 500-1,000 direct jobs in cultivation and processing, with additional employment in equipment manufacturing and logistics. Drug policy researchers have examined South Korea's program in comparative context. Dr. Jennifer Lee, a Korean-American researcher at the RAND Corporation, published a 2024 analysis comparing South Korea's pharmaceutical model to broader medical cannabis programs in North America and Europe. According to Lee's research, the Korean approach minimizes diversion risks and maintains social acceptability but creates significant access barriers through high costs and limited qualifying conditions. The study suggested that hybrid models incorporating both pharmaceutical products and regulated dispensary access might better balance competing policy goals.

What's Next

The National Assembly Health and Welfare Committee is scheduled to review the domestic cultivation bill during the September 2026 legislative session. The bill faces uncertain prospects, with conservative members expressing concerns about cultivation security and potential normalization of cannabis use. Proponents emphasize economic benefits and cost reduction for patients. Committee chairman Representative Park Wan-su has indicated that the committee will hold public hearings in August 2026 before proceeding to markup. If the cultivation bill advances, implementation would require 18-24 months for facility construction, licensing processes, and initial harvests. The Ministry of Food and Drug Safety would need to develop comprehensive cultivation regulations covering facility security, quality control, testing protocols, and waste disposal. The Ministry of Agriculture would establish licensing criteria and oversight mechanisms. The Ministry of Health and Welfare is conducting a review of qualifying conditions scheduled for completion in December 2026. The review will examine clinical evidence for chronic pain, PTSD, Parkinson's disease, and other conditions covered in international medical cannabis programs. Patient advocacy groups have submitted petitions supporting expansion, while medical associations have urged caution. The Ministry has indicated that any expansion would be incremental, potentially adding one or two conditions rather than broad liberalization. Insurance coverage remains a critical issue for program viability. The National Health Insurance Service is evaluating Epidiolex for coverage consideration, with a decision expected in early 2027. Coverage would require Health Technology Assessment demonstrating cost-effectiveness compared to conventional epilepsy treatments. Jazz Pharmaceuticals has submitted pharmacoeconomic data supporting coverage, while the NHIS has raised concerns about budget impact and precedent for other cannabis-derived medications. Clinical research infrastructure is expanding slowly. Seoul National University Hospital received Ministry approval in May 2026 to conduct a Phase II clinical trial of CBD for treatment-resistant epilepsy in Korean pediatric populations. The trial, funded by the Ministry of Health and Welfare, will enroll 60 patients over two years. Results could inform future policy decisions about expanded access and insurance coverage. Regional policy diffusion represents a longer-term consideration. Japan's Ministry of Health, Labour and Welfare has studied South Korea's program as it considers medical cannabis policy options. Taiwan's Food and Drug Administration has similarly examined the Korean framework. South Korea's experience as the first major East Asian nation to legalize medical cannabis, even in limited form, creates precedent that may influence regional policy development over the next 5-10 years. The pharmaceutical industry is watching for signals about market expansion. If domestic cultivation authorization passes and qualifying conditions expand, international companies may increase investment in Korean market development. Conversely, continued restrictions and low patient numbers may lead companies to deprioritize Korea in favor of larger Asian markets like Japan and Australia.

Further Reading

• Narcotics Control Act (Act No. 15939, amended November 23, 2018) - Full text available at https://www.law.go.kr (Korean language, official legal database)
• Ministry of Food and Drug Safety Medical Cannabis Regulations (MFDS Regulation No. 2019-12) - https://www.mfds.go.kr
• Ministry of Health and Welfare Qualifying Conditions Notice (MOHW Notice No. 2019-47) - https://www.mohw.go.kr
• Korean Medical Association Policy Statement on Medical Cannabis (2023) - https://www.kma.org
• Ministry of Agriculture Domestic Cultivation Feasibility Study (March 2026) - https://www.mafra.go.kr
• Jazz Pharmaceuticals Epidiolex Prescribing Information (Korean version) - https://www.jazzpharma.com
• Korean Epilepsy Association Medical Cannabis Access Report (2025) - https://www.epilepsykorea.org
• National Assembly Bill No. 2026-1247 (Domestic Cultivation Authorization) - https://www.assembly.go.kr
• RAND Corporation Comparative Analysis of Asian Medical Cannabis Policies (Lee, 2024) - https://www.rand.org
• Seoul National University Hospital Clinical Trial Registry Entry (CBD Epilepsy Trial) - https://cris.nih.go.kr